上海汇通能源股份有限公司 第一章 总 则 第一条 为提高上海汇通能源股份有限公司（以下简称公司）治理水平、规范本公 司董事会秘书的选任、履职、培训和考核工作、指导本公司董事会秘书之日常工作，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》《上海 证券交易所股票上市规则》等有关法律、法规、部门规章、规范性文件和《上海汇通能 源股份有限公司章程》（以下简称公司章程）的有关规定，制定本制度。 第二条 董事会秘书是公司董事会聘任的高级管理人员，对公司和董事会负责。 公司设董事会秘书一名，作为公司与上海证券交易所（以下简称证券交易所）之 间的指定联络人。 董事会秘书负责公司股东会和董事会会议的筹备、文件保管以及公司股东资料管 理，办理信息披露事务等事宜。 第三条 董事会秘书应当遵守公司章程，承担公司高级管理人员的有关法律责任， 对公司负有忠实和勤勉义务。公司章程关于董事的忠实义务和勤勉义务的规定，同时适 用于董事会秘书。 第四条 公司设立董事会办公室，董事会办公室为董事会秘书管理的工作部门。 第二章 任职资格 第五条 董事会秘书由董事会聘任或解聘。公司董事或其他高级管理人员可以兼任 董事会 ...

股票代码：600376 股票简称：首开股份 编号：临 2025-069 北京首都开发股份有限公司 第十届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京首都开发股份有限公司（以下简称"首开股份"或"公司"）第十届监 事会第十四次会议于 2025 年 8 月 25 日在公司会议室召开。本次会议的召开符合 《中华人民共和国公司法》《公司章程》及有关法律、法规的规定。 本次会议在会议召开十日前以书面通知的方式通知全体监事。本次会议由监 事会主席王宏伟先生主持。会议应参会监事三名，实参会监事三名，王宏伟先生、 陈刚先生、袁韶宇先生现场参会。 会议通过如下决议： （一）以 3 票赞成，0 票反对，0 票弃权，审议通过《关于公司<2025 年半 年度报告>及<2025 年半年度报告摘要>的议案》 公司监事会审核了公司 2025 年半年度报告的编制和审议程序,并认真阅读 了公司 2025 年半年度报告及摘要,监事会认为： （1）公司 2025 年半年度报告的编制和审议程序符合法律、法规、《公司章 程》及相关制 ...

证券代码：603198 证券简称：迎驾贡酒 公告编号：2025-014 安徽迎驾贡酒股份有限公司 第五届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 安徽迎驾贡酒股份有限公司（以下简称"本公司"或"公司"）于 2025 年 8 月 15 日以电话、电子邮件等方式发出会议通知，并于 2025 年 8 月 25 日在公司 会议室以现场方式召开第五届监事会第八次会议。会议应到监事 5 人，实到监事 次会议的召集、召开和表决程序符合《公司法》等法律法规和《公司章程》的有 关规定，会议合法有效。 二、监事会会议审议情况 特此公告。 安徽迎驾贡酒股份有限公司监事会 表决结果：同意 5 票；反对 0 票；弃权 0 票。议案获得通过。 监事会对《公司 2025 年半年度报告全文及其摘要》进行了审核，认为： 《公 司 2025 年半年度报告全文及其摘要》的编制和审议程序符合法律法规的规定， 半年度报告的内容和格式符合中国证监会和上海证券交易所的各项规定，其所包 含的信息真实、准确、完整地 ...

一、取消监事会情况 为进一步提高公司治理水平，促进公司规范运作，根据《中华人民共和国公 司法》及中国证监会于2025年3月最新发布的《上市公司章程指引》等相关法律、 法规和规范性文件的规定，结合公司实际情况，公司拟取消监事会，由董事会审 计委员会行使《公司法》规定的监事会的职权，并相应修订《公司章程》及附件 股票代码：600376 股票简称：首开股份 编号：临2025-066 北京首都开发股份有限公司 关于取消监事会并修订《公司章程》 及公司部分管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京首都开发股份有限公司（以下简称"首开股份"、"公司"或"本公司"） 于2025年8月25日召开了第十届董事会第四十七次会议、第十届监事会第十四次 会议，审议通过了《关于取消监事会并修订 <公司章程> 及其附件的议案》，该 议案尚需提请公司2025年第四次临时股东会审议。现将相关事项公告如下： 《股东会议事规则》《董事会议事规则》，同时废止《监事会议事规则》。 公司现任监事履职至本次新修订的《公司章程》经公司股东会审议通 ...

Group 1 - The board meeting of Yijiahe Technology Co., Ltd. was held on August 25, 2025, with all six directors present, including three who attended via telecommunication [1][2] - The meeting reviewed and approved the company's 2025 semi-annual report and its summary, with a unanimous vote of 6 in favor [2] - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, again with a unanimous vote of 6 in favor [2] - The board decided to revise certain company regulations to enhance governance and compliance with relevant laws and regulations, with all votes in favor [2]

Group 1 - The board of directors of Ningbo Fujia Industrial Co., Ltd. held its fifth meeting of the third session, where all nine directors attended, ensuring the meeting's legality and validity [1] - The board approved the 2025 semi-annual report and its summary, which was reviewed by the audit committee [2] - The board decided to cancel the supervisory board and amend the company's articles of association, transferring the supervisory powers to the audit committee [2][3] Group 2 - The board approved the formulation, revision, and abolition of certain corporate governance systems to comply with the latest legal requirements [3][4] - The board proposed to hold the first extraordinary general meeting of shareholders in 2025 on September 12, 2025 [5]

Group 1: Board Meeting Overview - The third meeting of the third board of directors of Suzhou Weichuang Electric Technology Co., Ltd. was held on August 25, 2025, with all six directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status as of June 30, 2025 [1][2] Group 2: Fund Management and Usage - The board approved a special report on the management and actual usage of raised funds for the first half of 2025, confirming compliance with relevant regulations and that funds were stored in dedicated accounts and used appropriately [2][3] Group 3: Profit Distribution and Capital Changes - The board approved a profit distribution plan for the first half of 2025, proposing a cash dividend of 1.50 yuan per 10 shares, which considers the company's profitability and cash flow [3][4] - The board approved a proposal to change the company's registered capital, increasing it from 211,375,274 yuan to 213,794,774 yuan due to stock incentive plan activities [4][5] Group 4: Governance and Incentive Plans - The board approved the formulation and revision of certain corporate governance systems to enhance operational standards [5][6] - The board approved the draft of the 2025 stock option incentive plan, aimed at attracting and retaining talent while aligning the interests of shareholders, the company, and employees [6][7] - The board approved the management measures for the implementation of the 2025 stock option incentive plan to ensure its successful execution [8] Group 5: Shareholder Meeting and Authorizations - The board proposed to convene the first temporary shareholders' meeting of 2025 on September 10, 2025, to discuss various matters [10] - The board sought authorization from the shareholders to handle matters related to the 2025 stock option incentive plan, including determining eligibility and managing the plan's execution [9][10]

General Principles - The rules are established to improve the corporate governance structure of Shenzhen QY Optoelectronics Co., Ltd. and ensure the board of directors exercises decision-making power legally, scientifically, and efficiently [1][2] - The rules are based on relevant laws, regulations, and the company's articles of association [1] Composition and Responsibilities of the Board - The board consists of eleven directors, including one chairman, two vice-chairmen, and one employee representative director, with independent directors making up at least one-third of the board [2] - The board has various powers, including convening shareholder meetings, executing shareholder resolutions, deciding on business plans and investment proposals, and managing internal structures [2][3][4] Board Meeting Procedures - The board must meet at least twice a year, with meetings convened by the chairman [16] - A temporary meeting can be proposed by shareholders or directors, requiring a notice period of three days unless urgent [16][18] - Decisions require a majority of directors present, and independent directors must attend personally or provide written opinions if absent [17][18] Voting and Decision-Making - Board resolutions are made through a voting process, requiring a majority approval from all directors [35][36] - Directors with conflicts of interest must abstain from voting on related matters [19][20] Committees - The board establishes specialized committees, including audit, nomination, compensation, and strategy committees, with independent directors holding a majority in certain committees [6][7] - Each committee is responsible for specific tasks, such as reviewing financial information, proposing director candidates, and evaluating executive compensation [6][7] Director Qualifications and Duties - Directors must be natural persons and cannot hold positions if they have certain legal or financial disqualifications [8][9] - Directors have fiduciary duties to act in the best interest of the company, avoid conflicts of interest, and maintain confidentiality [11][12][13] Amendments and Effectiveness - The rules will take effect upon approval by the shareholders and will be updated as necessary to comply with new laws or regulations [46][47]

Core Points - The articles outline the regulations and governance structure of Zhejiang Hisun Pharmaceutical Co., Ltd, emphasizing the protection of the rights of shareholders, employees, and creditors [1][3][4] - The company is established as a publicly listed joint-stock company with a registered capital of RMB 1,198.848196 million [2][7] - The company aims to be a leading pharmaceutical enterprise focusing on research and innovation, adhering to high production standards [5][6] Group 1: General Provisions - The company is established under the Company Law and other relevant regulations, with its legal representative being the chairman elected by the board [1][2] - The company has a permanent existence as a publicly listed joint-stock company [2] - The articles serve as a legally binding document governing the relationships and rights among the company, shareholders, and management [3][4] Group 2: Business Objectives and Scope - The company's business objective is to provide high-quality pharmaceutical products and health solutions globally, driven by research and innovation [5] - The business scope includes drug production, pharmaceutical wholesale, and various related activities, subject to legal approvals [5][6] Group 3: Shares - The company issues shares in the form of stocks, ensuring equal rights for all shares of the same category [7][8] - The total number of issued shares is 1,198,481,196, all of which are ordinary shares [7][8] - The company can provide financial assistance for acquiring its shares under specific conditions approved by the board [8][9] Group 4: Shareholder Rights and Meetings - Shareholders have rights to dividends, voting, and participation in company decisions, with equal rights for shares of the same category [14][15] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - Shareholder proposals must be submitted within a specified timeframe before meetings, ensuring transparency and participation [58][59]

Core Viewpoint - The Shandong Pharmaceutical Glass Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss significant governance changes, including the abolition of the supervisory board and amendments to the company's articles of association and meeting rules [1][2][4]. Meeting Details - The meeting will take place on September 12, 2025, at 15:00, with both on-site and online voting options available for shareholders [1][2]. - The location of the meeting is the R&D building of Shandong Pharmaceutical Glass Co., Ltd. in Yiyuan County, Zibo City, Shandong Province [2]. Agenda Items - **Proposal 1**: Abolishment of the supervisory board and the corresponding rules, transferring its powers to the audit committee of the board of directors, ensuring compliance with updated regulations [2][4]. - **Proposal 2**: Amendments to the company's articles of association to enhance governance structure and operational standards, in line with the latest regulatory requirements [4][5]. - **Proposal 3**: Revisions to the rules governing shareholder meetings to align with the adjustments in governance structure and regulatory compliance [5][6]. - **Proposal 4**: Updates to the rules governing board meetings to ensure continued adherence to regulatory standards and improve governance practices [6][7].